Clinical Impact:

• Early detection of progression
• Development of anti-fibrotic drug therapies
• Management with FDA approved anti-fibrotic drugs (pirfenidone and nintedanib)

Publications:

• Hahn and Kammerman et al, J Magn Reson Imaging. 2019 Oct;50(4):1182-1190.
• Hahn et al., Radiology  Vol. 305, No. 3 (2022).
• Hahn et al., ERJ Open Research (2023).
• Leewiwatwong, S., A.  et al. Magn Reson Med 94, no. 4 (Oct 2025): 1684-99.

Funding:

NIH NCATS S10OD026960;

S10OD025025;

NIH NHLBI R01 HL126774;

CTSA program grant UM1TR004403